牛牛AI助理已提取核心訊息
Avenue Therapeutics, Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on January 24, 2024, for the registration of 33,080,598 shares of common stock. The registration statement includes a preliminary prospectus detailing the proposed sale of shares by selling stockholders from time to time after the effective date of the Registration Statement. The sale may occur on the Nasdaq Capital Market or through private transactions at fixed or negotiated prices. The company will not receive any proceeds from the sale of shares by the selling stockholders. The registration statement also outlines the rights and obligations of the selling stockholders, including the potential methods of sale, such as block trades, broker transactions, or directly to purchasers. Avenue Therapeutics, a specialty pharmaceutical company, has indicated that the registration is part of its efforts to satisfy certain registration rights granted to the selling stockholders. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ATXI'.
Avenue Therapeutics, Inc. has filed a Form S-3 with the Securities and Exchange Commission (SEC) on January 24, 2024, for the registration of 33,080,598 shares of common stock. The registration statement includes a preliminary prospectus detailing the proposed sale of shares by selling stockholders from time to time after the effective date of the Registration Statement. The sale may occur on the Nasdaq Capital Market or through private transactions at fixed or negotiated prices. The company will not receive any proceeds from the sale of shares by the selling stockholders. The registration statement also outlines the rights and obligations of the selling stockholders, including the potential methods of sale, such as block trades, broker transactions, or directly to purchasers. Avenue Therapeutics, a specialty pharmaceutical company, has indicated that the registration is part of its efforts to satisfy certain registration rights granted to the selling stockholders. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'ATXI'.
Avenue Therapeutics, Inc.已於2024年1月24日向美國證券交易委員會（SEC）提交了S-3表格，要求註冊33,080,598股普通股。註冊聲明包括初步招股說明書，詳細說明了在註冊聲明生效之日後不時出售股東的提議。出售可以在納斯達克資本市場上進行，也可以通過私人交易以固定或協議價格進行。該公司不會從出售股票的股東那裏獲得任何收益。註冊聲明還概述了出售股東的權利和義務，包括潛在的出售方式，例如大宗交易、經紀交易或直接向買方交易。專業製藥公司Avenue Therapeutics表示，此次註冊是其滿足授予出售股東的某些註冊權的努力的一部分。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “ATXI”。
Avenue Therapeutics, Inc.已於2024年1月24日向美國證券交易委員會（SEC）提交了S-3表格，要求註冊33,080,598股普通股。註冊聲明包括初步招股說明書，詳細說明了在註冊聲明生效之日後不時出售股東的提議。出售可以在納斯達克資本市場上進行，也可以通過私人交易以固定或協議價格進行。該公司不會從出售股票的股東那裏獲得任何收益。註冊聲明還概述了出售股東的權利和義務，包括潛在的出售方式，例如大宗交易、經紀交易或直接向買方交易。專業製藥公司Avenue Therapeutics表示，此次註冊是其滿足授予出售股東的某些註冊權的努力的一部分。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “ATXI”。
有用
沒用